Investigational drugs for the treatment of malignant melanoma.
D000477:Alkylating Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000577:Amides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000856:Anorexia Nervosa / Q000138:chemical synthesis; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007970:Leukopenia / Q000139:chemically induced; D008545:Melanoma / Q000188:drug therapy*; D009325:Nausea / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D000477:Alkylating Agents; D000577:Amides; D000970:Antineoplastic Agents; D004338:Drug Combinations; D007093:Imidazoles; D003609:Dactinomycin; D003520:Cyclophosphamide; D006918:Hydroxyurea